The production of adenosine via CD39 and CD73 enzymes participates in an immunosuppressive tumor microenvironment. Perrot et al. generated two antibodies, IPH5201 and IPH5301, targeting human CD39 and...

Cash, cash equivalents and financial assets of the Company amounted to €237.1 million* Initiation of cohort expansion study of monalizumab and cetuximab to evaluate triple combination with an anti-PD...

Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) will hold its Annual General Meeting of Shareholders (“AGM”) on May 22, 2019, at 11:00 AM in its headquarters, 117 avenue de Luminy...

New preclinical data highlights IPH5201 (anti-CD39) and IHP5301 (anti-CD73) neutralizing antibodies targeting the immunosuppressive adenosine pathway First data presented from Innate Pharma’s...

Cash, cash equivalents and financial assets* amounted to €202.7m (million euros) as of December 31, 2018 (€176.6m in 2017) Revenue and other income amounted to €94.0m (€36.2m in 2017) Operating...

Commercial industry leader with immuno-oncology product launch experience joins Innate’s Executive Committee General Manager will lead the Lumoxiti ® transition to Innate Pharma from AstraZeneca...

Appointments of Dr. Mondher Mahjoubi, Chief Executive Officer, and Dr. Yannis Morel, EVP Business Development and Portfolio Strategy, renewed to the Executive Board for three years Innate Pharma SA...

Fast Track designation (FTD) is intended to expedite the development and regulatory review of IPH4102 for the treatment of adult patients with relapsed or refractory Sézary syndrome (SS) who have...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces its financial calendar for 2019, which is set as follows: March 20, 2019: Publication of 2018 financial statements...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that it will be present at the following investor events in the first quarter 2019: - LifeSci Advisors 1x1...